Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma
Launched by CHILDREN'S CANCER AND LEUKAEMIA GROUP · Jan 26, 2003
Trial Information
Current as of August 30, 2025
Unknown status
Keywords
ClinConnect Summary
OBJECTIVES:
* Determine the efficacy of induction chemotherapy followed by surgical resection and consolidation chemotherapy with autologous peripheral blood stem cell transplantation in patients with metastatic neuroblastoma.
* Determine the tolerability and feasibility of this regimen in these patients.
* Determine the medium and long-term results in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive induction chemotherapy comprising cyclophosphamide IV over 6 hours on days 1 and 2 and doxorubicin IV continuously and vincristine IV continuously o...
Gender
ALL
Eligibility criteria
- DISEASE CHARACTERISTICS:
- • Histologically or cytologically confirmed primary neuroblastoma OR
- • Presence of neuroblasts in bone marrow associated with an elevation of urinary catecholamines
- * Metastatic disease demonstrated by at least 1 of the following:
- • Medullary invasion (bone marrow involvement) as indicated by bone uptake on meta-iodobenzyl guanidine I 123 or bone lesions on bone scan
- • Distant metastases to liver, pleura, lungs, or distant nodes
- • No 11-22 translocation
- PATIENT CHARACTERISTICS:
- Age:
- • 1 and over
- Performance status:
- • Not specified
- Life expectancy:
- • Not specified
- Hematopoietic:
- • Not specified
- Hepatic:
- • Not specified
- Renal:
- • See Disease Characteristics
- Other:
- • No contraindications to study drugs
- PRIOR CONCURRENT THERAPY:
- • Biologic therapy
- • Not specified
- • Chemotherapy
- • No prior chemotherapy
- • No other concurrent chemotherapy
- • Endocrine therapy
- • Not specified
- • Radiotherapy
- • Not specified
- • Surgery
- • Not specified
About Children's Cancer And Leukaemia Group
The Children's Cancer and Leukaemia Group (CCLG) is a leading organization dedicated to improving outcomes for children and young people diagnosed with cancer and leukaemia. Comprising a network of healthcare professionals, researchers, and patient advocates, CCLG focuses on fostering collaboration and innovation in clinical research. The group is committed to developing and implementing clinical trials that advance treatment options, enhance patient care, and ultimately provide hope for families facing these challenging diagnoses. By prioritizing evidence-based practices and patient-centered approaches, CCLG aims to drive progress in pediatric oncology and improve survival rates and quality of life for affected children.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Villejuif, , France
Patients applied
Trial Officials
Janice A. Kohler, MD, FRCP
Study Chair
University Hospital Southampton NHS Foundation Trust
D. Valteau-Couanet
Study Chair
Gustave Roussy, Cancer Campus, Grand Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials